Antimuscarinics (formerly termed 'anticholinergics') reduce
intestinal motility and may be useful in irritable bowel syndrome
and in diverticular disease. Other indications of antimuscarinic
drugs include arrhythmias (section 2.3.1), asthma and airways
disease (section 3.1.2), motion sickness (section 4.6),
parkinsonism (section 4.9.2), urinary incontinence (section 7.4.2),
mydriasis and cycloplegia (section 11.5), premedication (section
15.1.3) and as an antidote to organophosphorus poisoning (
Emergency treatment of poisoning).
Antimuscarinics that are used for gastro-intestinal smooth muscle
spasm include the tertiary amines atropine sulphate and
dicycloverine hydrochloride (dicyclomine
hydrochloride) and the quaternary ammonium compounds
propantheline bromide and hyoscine butylbromide. The
quaternary ammonium compounds are less lipid soluble than
atropine and so may be less likely to cross the blood-brain barrier;
they are also less well absorbed. Although central atropine-like
side-effects, such as confusion, are thereby reduced, peripheral
side-effects are common with quaternary ammonium compounds.
Propantheline bromide is indicated as an adjunct in the treatment
of gastro-intestinal disorders characterised by smooth muscle
spasm (including non-ulcer dyspepsia and irritable bowel
syndrome); atropine sulphate is also licensed for these indications.
Dicycloverine hydrochloride (dicyclomine hydrochloride) has a
much less marked antimuscarinic action than atropine and may
also have some direct action on smooth muscle. Hyoscine
butylbromide is advocated as a gastro-intestinal antispasmodic,
but it is poorly absorbed; the injection is useful in endoscopy and
radiology. Atropine and the belladonna alkaloids are outmoded
treatments, any clinical virtues being outweighed by atropinic
side-effects.
CAUTIONS. Antimuscarinics should be used with caution (due to
increased risk of side-effects) in Down's syndrome, in children and
in the elderly; they should also be used with caution in
gastro-oesophageal reflux disease, diarrhoea, ulcerative colitis,
acute myocardial infarction, hypertension, conditions characterised
by tachycardia (including hyperthyroidism, cardiac insufficiency,
cardiac surgery), pyrexia, pregnancy and breast-feeding.
Interactions: Appendix 1 (antimuscarinics).
CONTRA-INDICATIONS. Antimuscarinics are contra-indicated in
angle-closure glaucoma, myasthenia gravis (but may be used to
decrease muscarinic side-effects of anticholinesterases?section
10.2.1), paralytic ileus, pyloric stenosis and prostatic enlargement.
SIDE-EFFECTS. Side-effects of antimuscarinics include constipation,
transient bradycardia (followed by tachycardia, palpitations and
arrhythmias), reduced bronchial secretions, urinary urgency and
retention, dilatation of the pupils with loss of accommodation,
photophobia, dry mouth, flushing and dryness of the skin.
Side-effects that occur occasionally include confusion (particularly
in the elderly), nausea, vomiting and giddiness.

|
BNF |
|
|
|

PROPANTHELINE BROMIDE
Indications: symptomatic relief of gastro-intestinal disorders
characterised by smooth muscle spasm; urinary frequency (section
7.4.2); gustatory sweating (section 6.1.5)
Cautions: see notes above
Contra-indications: see notes above
Side-effects: see notes above
Dose: 15 mg 3 times daily at least 1 hour before meals and 30 mg
at night, max. 120 mg daily; CHILD not recommended
Propantheline has no specific interaction information.
Propantheline belongs to Antimuscarinics and will have the following
interactions of Antimuscarinics:
Many drugs have antimuscarinic effects; concomitant use of two or
more such drugs can increase side-effects such as dry mouth, urine
retention, and constipation; concomitant use can also lead to confusion
in the elderly
Interactions do not generally apply to antimuscarinics used by inhalation
Amantadine |
Increased antimuscarinic side-effects |
Antidepressants,
Tricyclic |
Increased antimuscarinic side-effects |
Antidepressants,
Tricyclic (related) |
Possibly increased antimuscarinic
side-effects |
Antihistamines  |
Increased antimuscarinic side-effects |
Clozapine  |
Increased antimuscarinic side-effects |
Disopyramide |
Increased antimuscarinic effects |
Domperidone |
Antagonism of effect on gastro-intestinal
activity |
Ketoconazole |
Reduced absorption of ketoconazole |
Levodopa |
Absorption of levodopa possibly reduced |
MAOIs  |
Increased antimuscarinic side-effects |
Metoclopramide |
Antagonism of effect on gastro-intestinal
activity |
Nefopam |
Increased antimuscarinic effects |
Nitrates |
Possibly reduced effect of sublingual nitrates
(failure to dissolve under the tongue owing to
dry mouth) |
Parasympathomimetics |
Antagonism of effect |
Phenothiazines |
Increased antimuscarinic side-effects of
phenothiazines (but reduced plasma
concentrations) |
출처 : BNF(British National Formulary )